Skip to content

Study · Non-randomized trial · n = 22 · 1996

4 results

Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.

Avrech OM, Goldman GA, Pinkas H, Amit S, Neri A, Zukerman Z, Ovadia J, Fisch B

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Jun 1996Cited by 2 (Europe PMC)

PMID8862491 (opens in a new tab)DOI10.3109/09513599609027984 (opens in a new tab)PepBankPUB-08862491
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In paired IVF cycles, nafarelin and buserelin cycles did not differ significantly in baseline hormone profile, duration of GnRH analog treatment, mean hMG dose, peak estradiol, number of preovulatory follicles, number of aspirated oocytes, fertilization rate, or number of transferred or frozen embryos.

    In plain wordsNafarelin and buserelin cycles did not differ significantly in the hormone, hMG dose, follicle, oocyte, fertilization, or embryo measures the study listed.

    Peptide
    Nafarelin
    Outcome
    No significant changeOvarian stimulation and IVF parameters
    Study

    n = 22

    Comparator
    Buserelin cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    The buserelin and nafarelin cycles did not differ significantly in the following parameters: baseline hormone profile, duration of GnRH analog treatment, mean hMG dose required, peak estradiol levels, number of preovulatory follicles, number of aspirated oocytes, fertilization rate and number of tra…
    2 context sentences
    Summary · context
    Each underwent two consecutive treatment cycles; one with buserelin (900 micrograms/day) and another with nafarelin (400 micrograms/day).
    Summary · context
    The treatment protocol included transnasal gonadotropin-releasing hormone (GnRH) analog from the second cycle day and hMG from the fourth day of the cycle.
  2. 02HumanNon-randomized trialSafety outcome

    In paired IVF cycles using nafarelin or buserelin, no side effects were recorded.

    In plain wordsNo side effects were recorded in the nafarelin or buserelin IVF cycles.

    Peptide
    Nafarelin
    Outcome
    Not applicableSide effects
    Study

    n = 22

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    400 micrograms/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    No side-effects or cancellations of treatment were recorded.
    2 context sentences
    Summary · context
    Each underwent two consecutive treatment cycles; one with buserelin (900 micrograms/day) and another with nafarelin (400 micrograms/day).
    Summary · context
    The treatment protocol included transnasal gonadotropin-releasing hormone (GnRH) analog from the second cycle day and hMG from the fourth day of the cycle.
  3. 03HumanNon-randomized trialSafety outcome

    In paired IVF cycles using nafarelin or buserelin, no treatment cancellations were recorded.

    In plain wordsNo treatment cancellations were recorded in the nafarelin or buserelin IVF cycles.

    Peptide
    Nafarelin
    Outcome
    Not applicableTreatment cancellation
    Study

    n = 22

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    400 micrograms/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    No side-effects or cancellations of treatment were recorded.
    2 context sentences
    Summary · context
    Each underwent two consecutive treatment cycles; one with buserelin (900 micrograms/day) and another with nafarelin (400 micrograms/day).
    Summary · context
    The treatment protocol included transnasal gonadotropin-releasing hormone (GnRH) analog from the second cycle day and hMG from the fourth day of the cycle.
  4. 04HumanNon-randomized trialEfficacy outcome

    In paired IVF cycles, the average required nafarelin dose was lower than the required buserelin dose.

    In plain wordsNafarelin required a lower average dose than buserelin in paired IVF cycles.

    Peptide
    Nafarelin
    Outcome
    DecreaseAverage dose required
    Study

    n = 22

    Comparator
    Buserelin cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 micrograms/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    The average dose required was lower for nafarelin and, because this analog was given only twice a day, it was more convenient to administer.
    2 context sentences
    Summary · context
    Each underwent two consecutive treatment cycles; one with buserelin (900 micrograms/day) and another with nafarelin (400 micrograms/day).
    Summary · context
    The treatment protocol included transnasal gonadotropin-releasing hormone (GnRH) analog from the second cycle day and hMG from the fourth day of the cycle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.